The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
Open accessAbstract
In patients with type 1 diabetes, measurement of connecting peptide (C-peptide), cosecreted with insulin from the islets of Langerhans, permits estimation of remaining β-cell secretion of insulin. In this retrospective analysis to distinguish the incremental benefits of residual β-cell activity in type 1 diabetes, stimulated (90 min following ingestion of a mixed meal) C-peptide levels at entry in the Diabetes Control and Complications Trial (DCCT) were related to measures of diabetic retinopathy and nephropathy and to incidents of severe hypoglycemia. Based on the analytical sensitivity of the assay (0.03 nmol/l) and study entry criteria, the DCCT subjects were divided into four groups of stimulated C-peptide responses: ≤0.03, 0.04–0.20, 0.21–0.50 nmol/l at entry, and 0.21–0.50 nmol/l at entry and at least 1 year later (sustained C-peptide secretion). Uniformly in the intensive and partially in the conventional DCCT treatment groups, any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy (both a single three-step change and a repeated three-step change on the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale at the next 6 month visit) and nephropathy (both albuminuria >40 mg/24 h once and repeated at the next annual visit). There were also differences in severe hypoglycemia across C-peptide levels in both treatment groups. In the intensively treated cohort there were essentially identical prevalences of severe hypoglycemia (∼65% of participants) in the first three groups; however, those subjects with mixed-meal stimulated C-peptide level >0.20 nmol/l for at least baseline and the first annual visit in the DCCT experienced a reduced prevalence of ∼30%. Therefore, even modest levels of β-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy. Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although this endogenous secretion is typically low, maintenance is important since it is associated with less retinopathy and less severe hypoglycaemia at later stages of the disease.86”
From Type 1 diabetes (2014) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding is noteworthy because in the Diabetes Control and Complications Trial68,69 persistent C-peptide secretion was associated with reduced development of retinopathy, nephropathy, and hypoglycaemia.”
From Type 1 diabetes (2018) · cites this paper as [69]
In the citing paper
“In addition, we analysed two other thresholds: UCPCR≥0.03 nmol/mmol and ≥0.2nmol/mmol, which are equivalent to serum C peptide of 30 pmol/L (a common historical limit of detection(3; 11; 12)) and 200 pmol/L (a clinically defined level associated with reduced microvascular complications and hypoglycaemia(13)).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
The DCCT Research Group (1986) · Diabetes · doi:10.2337/diabetes.35.5.530 · Cited by 466
(1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100010038019 · Cited by 325
Hypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
THE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 215
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 697
Wang, Y., Gao, Y., Cai, X., Chen, L., Zhou, L., Ma, Y., Gong, S., Han, X., & Ji, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1747684 · Cited by 14
Andersen, M. L. M., Nielsen, L. B., Svensson, J., Pörksen, S., Hougaard, P., Beam, C. A., Greenbaum, C. J., BECKER, D. J., Petersen, J. S., Hansen, L. B., et al. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12098 · Cited by 13
Molecular Effects of C-Peptide in Microvascular Blood Flow Regulation
Forst, T. M., Hach, T., Kunt, T., Weber, M. M., & Pfützner, A. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.159 · Cited by 13
Review: The importance of residual endogenous beta-cell preservation in type 1 diabetes
Ali, M. A., & Dayan, C. M. (2009) · The British Journal of Diabetes · doi:10.1177/1474651409351881 · Cited by 13
Current and future management of diabetic retinopathy: a personalized evidence-based approach
Fante, R. J., Gardner, T. W., & Sundstrom, J. M. (2013) · Diabetes Management · doi:10.2217/dmt.13.50 · Cited by 13
Pietropaolo, M. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283628610 · Cited by 13
Ehlers, M. R., & Nepom, G. T. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.359 · Cited by 15
Ren, W., Yang, D., Jiang, Z., Xian, Y., Huang, Q., Luo, S., Zheng, X., Yan, J., Xu, W., Yao, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3357 · Cited by 13
Accili, D. (2020) · New England Journal of Medicine · doi:10.1056/nejme2030472 · Cited by 13
Suh, J., Lee, H. I., Lee, M., Song, K., Choi, H. S., Kwon, A., Kim, H.-S., & Chae, H. W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.869204 · Cited by 13
Qureshi, F. M., Panzer, J. K., Põder, J., Malek, T. R., & Caicedo, A. (2023) · Diabetes · doi:10.2337/db22-0482 · Cited by 12
Piemonti, L., Melzi, R., Aleotti, F., Capretti, G. L., Nano, R., Mercalli, A., Magistretti, P., Caldara, R., Pecorelli, N., Catarinella, D., et al. (2024) · Transplantation · doi:10.1097/tp.0000000000005037 · Cited by 12
Lu, B., Li, P., Crouse, A. B., Grimes, T., Might, M., Ovalle, F., & Shalev, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae516 · Cited by 12
Kidney Disease: The Forgotten Legacy of Type 1 Diabetes
Thomas, M. C., Zoungas, S., Hanssen, N. M. J., McAuley, S. A., & Cooper, M. E. (2025) · Diabetes Care · doi:10.2337/dci25-0028 · Cited by 15
Xiang, H., Yang, C., Xiang, T., Wang, Z., Ge, X., Li, F., Su, Y., Chen, H., Huang, X., & Zeng, Q. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0144 · Cited by 12
Treatment of Latent Autoimmune Diabetes in Adults: What is Best?
Hals, I. K. (2019) · Current Diabetes Reviews · doi:10.2174/1573399814666180716144429 · Cited by 12
Cheng, J., Yin, M., Tang, X., Yan, X., Xie, Y., He, B., Li, X., & Zhou, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7471 · Cited by 12
Carr, A. L. J., Oram, R. A., Marren, S. M., McDonald, T. J., Narendran, P., & Andrews, R. C. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab127 · Cited by 12
The heterogeneity of type 1 diabetes: From immunopathology to immune intervention
Infante, M., Alejandro, R., Fabbri, A., & Ricordi, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824466-1.00001-7 · Cited by 12
Vitamin D and Omega 3 Field Study on Progression of Type 1 Diabetes.
Ricordi, C., Clare-Salzler, M. J., Infante, M., Baggerly, C. A., Aliano, J. L., McDonnell, S. L., & Chritton, S. (2019) · PubMed · doi:10.32113/cellr4_20198_2737 · Cited by 12
Strategies to prevent type 1 diabetes
Thrower, S., & Bingley, P. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01064.x · Cited by 12
Yin, P., Shao, P., Liu, H., Li, W., Wang, L., Wang, J., Zhang, S., Leng, J., Li, N., Tian, H., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.08.006 · Cited by 12
Capturing residual beta cell function in type 1 diabetes
Pociot, F. (2018) · Diabetologia · doi:10.1007/s00125-018-4768-y · Cited by 12
The Evolution of Type 1 Diabetes
Skyler, J. S., & Sosenko, J. M. (2013) · JAMA · doi:10.1001/jama.2013.6286 · Cited by 12
Vasilev, G., Kokudeva, M., Siliogka, E., Padilla, N., Shumnalieva, R., Della‐Morte, D., Ricordi, C., Mihova, A., Infante, M., & Velikova, T. V. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.99936 · Cited by 11
Factor analysis of diabetic nephropathy in Chinese patients
Zheng, W., & Chen, L. (2011) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2012.02.018 · Cited by 11
Clinical and demographic features among patients with type 1 diabetes mellitus in Henan, China
Yang, L., Yang, G., & Li, X. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00799-2 · Cited by 11
Nwosu, B. U., Parajuli, S., Khatri, K., Jasmin, G., Al‐Halbouni, L., & Lee, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.705565 · Cited by 11
The Theory of Hyperlipidemic Memory of Type 1 Diabetes
Nwosu, B. U. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.819544 · Cited by 11
Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies
Beam, C. A., Gitelman, S. E., Palmer, J. P., & the Type 1 Diabetes TrialNet Study Group (2014) · Diabetes · doi:10.2337/db14-0095 · Cited by 11
Heywood, J. J. N., Evangelou, M., Donna, G., Kennet, J., Katerina, A., Guy, C., O’Brien, C., Nutland, S. L., Judy, B., Walker, N. M., et al. (2015) · Trials · doi:10.1186/s13063-015-0583-7 · Cited by 13
Landgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/a-0598-0475 · Cited by 11
Cui, L., Lv, N., Li, B., Tao, J., Xiaomin, Z., Yan, Y., & Liu, C. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0994-9970 · Cited by 11
A secreção residual do peptídeo C faz diferença no tratamento do diabetes melito tipo 1?
Rodacki, M., Milech, A., & de Oliveira, J. E. P. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000200020 · Cited by 12
Bouillet, B., Rouland, A., Petit, J., & Vergès, B. L. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.06.004 · Cited by 11
Drug Insight: new immunomodulatory therapies in type 1 diabetes
Cernea, S., & Herold, K. C. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0082 · Cited by 11
Cryer, P. E. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch33 · Cited by 11
C-peptide in Precision Diabetes Care and Beyond: A Comprehensive Review
Eligar, V. S., Rao, B. L. N., Naqvi, S., & Gautam, D. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514251397811 · Cited by 10
Recent Advances in the Prevention of Hypoglycemia in Type 1 Diabetes
Realsen, J., & Chase, H. P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0150 · Cited by 10
Pomposelli, T., Schuetz, C., Wang, P., & Yamada, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.632605 · Cited by 11
Narendran, P., Tomlinson, C. L., Beese, S. E., Sharma, P., Harris, I. M., Adriano, A., Maggs, F., Burrows, M., Nirantharakumar, K., Thomas, G. N., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14730 · Cited by 10
Ipp, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.734360 · Cited by 10
Nwosu, B. U. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884219 · Cited by 12
Verapamil and Its Role in Diabetes
Zimmermann, P., Aberer, F., Eckstein, M. L., Haupt, S., Erlmann, M. P., & Moser, O. (2022) · Diabetology · doi:10.3390/diabetology3030030 · Cited by 10
Complete remission in children and adolescents with type 1 diabetes mellitus—prevalence and factors
Podoláková, K., Barák, Ľ., Jancova, E., Tárnoková, S., Podracká, Ľ., Dobiašová, Z., Škopková, M., Gašperíková, D., & Staník, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-34037-7 · Cited by 11
Honeymoon phase in type 1 diabetes mellitus: A window of opportunity for diabetes reversal?
Mittal, M., Porchezhian, P., & Kapoor, N. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i1.9 · Cited by 10
Wherrett, D. K., & Daneman, D. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.07.010 · Cited by 10
Akinlade, A. T., Ogbera, A. O., Fasanmade, O. A., & Olamoyegun, M. A. (2014) · International Archives of Medicine · doi:10.1186/1755-7682-7-50 · Cited by 11
GAD65: a prospective vaccine for treating Type 1 diabetes?
Ludvigsson, J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1328495 · Cited by 10
Walkey, H. C., Kaur, A., Bravis, V., Godsland, I. F., Misra, S., Williams, A. J. K., Bingley, P. J., Dunger, D. B., Oliver, N. S., & Johnston, D. G. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013956 · Cited by 10
Factors Associated with C-peptide Levels after Diagnosis in Children with Type 1 Diabetes Mellitus
Hwang, J. W., Kim, M. S., & Lee, D. (2017) · Chonnam Medical Journal · doi:10.4068/cmj.2017.53.3.216 · Cited by 10
Yang, X., Xu, W., Zhu, Y., Deng, H., Tan, Y. C. R. S., Zeng, L., & Weng, J. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0304-9 · Cited by 10
Lagarde, W. H., Courtney, K. L., Reiner, B. J., Steinmann, K., Tsalikian, E., & Willi, S. M. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13162 · Cited by 10
Goffinet, L., Barrea, T., Beauloye, V., & Lysy, P. A. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816681706 · Cited by 10
The Epidemiology of Diabetic Retinopathy
Klein, R., & Klein, R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00045-x · Cited by 10
Nwosu, B. U. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.974196 · Cited by 9
Maddaloni, E., Naciu, A. M., Mignogna, C., Galiero, R., Amendolara, R., Fogolari, M., Satta, C., Serafini, C., Angeletti, S., Cavallo, M. G., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15469 · Cited by 9
Leão, I. S., Dantas, J. R., Araújo, D. B., Ramos, M. E. N., Silva, K. R., Batista, L. S., Pereira, M. D. F. C., Luiz, R. R., da Silva, C. C., Maiolino, Â., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01302-2 · Cited by 9
Serfaty, F. M., Dantas, J. R., de Almeida, M. H., Duarte, J. D. G., Kupfer, R., Campos, F., Zajdenverg, L., Milech, A., Rodacki, M., & de Oliveira, J. E. P. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000500004 · Cited by 9
Can the AHCL System Be Used in T1D Patients with Borderline TDDI? A Case Report
Tekielak, A., Seget, S., Rusak, E., & Jarosz-Chobot, P. A. (2021) · Sensors · doi:10.3390/s21217195 · Cited by 9
Ludvigsson, J., Eriksson, L., Nowak, C., Teixeira, P. F., Widman, M., Lindqvist, A., Casas, R., Lind, M., & Hannelius, U. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061776 · Cited by 10
Grönberg, A., Espes, D., Carlsson, P., & Ludvigsson, J. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002991 · Cited by 9
Reddy, R., Dayal, D., Sachdeva, N. K., Attri, S. V., & Gupta, V. K. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022ao0149 · Cited by 9
Pan, T., Gao, J., Cai, X., Zhang, H., Lü, J., & Lei, T. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01300-x · Cited by 9
Pinheiro, M. M., Pinheiro, F. M. M., Garo, M. L., Pastore, D., Pacifici, F., Ricordi, C., Della‐Morte, D., & Infante, M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.12 · Cited by 9
Xiang, H., Chen, H., Li, F., Liu, J., Su, Y., Hao, L., Wang, F., Wang, Z., & Zeng, Q. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.07.006 · Cited by 9
Carroll, K. R., Elfers, E. E., Stevens, J., McNally, J. P., Hildeman, D. A., Jordan, M. B., & Katz, J. D. (2018) · Diabetes · doi:10.2337/db18-0204 · Cited by 10
Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds
de Almeida, M. H., Dantas, J. R., Barone, B., Serfaty, F. M., Kupfer, R., Albernaz, M. D. S., Bencke, M. R., Zajdenverg, L., Rodacki, M., & de Oliveira, J. E. P. (2013) · Clinics · doi:10.6061/clinics/2013(01)rc02 · Cited by 9
GAD-alum (Diamyd) – a new concept for preservation of residual insulin secretion
Ludvigsson, J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003742920 · Cited by 9
Li, X., Cheng, J., Huang, G., Luo, S., & Zhou, Z. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12907 · Cited by 9
Hill, H., Lundkvist, P., Tsatsaris, G., Birnir, B., Espes, D., & Carlsson, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-95751-y · Cited by 9
Zhang, L., Xu, Y., Jiang, X., Wu, J., Liu, F., Fan, L., Li, X., Yin, G., & Yang, L. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13693 · Cited by 8
Snethlage, C. M. F., Balvers, M., Ferwerda, B., Rampanelli, E., de Groen, P., Roep, B. O., Herrema, H., McDonald, T. J., van Raalte, D. H., Weedon, M. N., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06204-6 · Cited by 8
Amendolara, R., Zampetti, S., Siena, A., D’Onofrio, L., Vita, F. D., Barbaro, F., Notarnicola, D., Sessa, R. L., Luverà, D., Risi, R., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112006 · Cited by 10
Ismail, H. M., Evans‐Molina, C., DiMeglio, L. A., Becker, D. J., Libman, I. M., Sims, E. K., Boulware, D. C., Herold, K. C., Rafkin, L. E., Skyler, J. S., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12845 · Cited by 9
Nowak, C., Hannelius, U., & Ludvigsson, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14720 · Cited by 8
Th2 cell clonal expansion at diagnosis in human type 1 diabetes
Narsale, A. A., Almanza, F., Tran, T., Lam, B., Seo, D., Vu, A., Long, S. A., Cooney, L., Serti, E., & Davies, J. D. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109829 · Cited by 8
Rydén, A., Bolmeson, C., Jonson, C., Cilio, C., & Faresjö, M. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1286 · Cited by 8
Following the Fate of the Failing β-Cell: New Insights From First-Phase Insulin Responses
Williams, A. J. K., & Long, A. E. (2013) · Diabetes · doi:10.2337/db13-1314 · Cited by 8
Chan, C. L., Taki, I., Dong, F., Hoffman, M., Norris, J. M., KLINGENSMITH, G. J., Rewers, M., & Steck, A. K. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0029 · Cited by 8
Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes
Pilla, S. J., Quan, A. Q., Germain‐Lee, E. L., Hellmann, D. B., & Mathioudakis, N. N. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0792-9 · Cited by 8
Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes
Nwosu, B. U., Villalobos-Ortiz, T. R., Jasmin, G., Parajuli, S., Zitek‐Morrison, E., & BARTON, B. A. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2020-0220 · Cited by 8
de Groen, P., Snethlage, C. M. F., Wortelboer, K., Tokgöz, S., Davids, M., Verdoes, X., Westerbeke, F. H. M., Meijer, R. I., Gotthardt, M., de Vos, W. M., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2563155 · Cited by 7
Wagner, R. J., Füchtenbusch, M., Hummel, M., Miszon, M., Pfützner, A., Tan, S., & Wiesner, T. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113047 · Cited by 7
Penaforte-Saboia, J. G., Couri, C. E. B., Fernandes, V. O., Montenegro, A. P. D. R., Batista, L. A. D. A., Zajdenverg, L., Negrato, C. A., Malmegrim, K. C. R., Moraes, D. A., Dias, J. B. E., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00747 · Cited by 7
Prediction of Hypoglycemia in Diabetic Patients During Colonoscopy Preparation
Lü, X., Xie, L., Zhao, W., Zhang, C., Luo, X., & Zhou, Y. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2044-0685 · Cited by 7
Giannakopoulos, A., Chrysanthakopoulou, N., Efthymiadou, A., & Chrysis, D. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108667 · Cited by 7
Importance of residual insulin secretion in type 1 diabetes
Skyler, J. S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00149-3 · Cited by 8
Verapamil improves One-Year C-Peptide Levels in Recent Onset Type-1 Diabetes: A Meta-Analysis
Dutta, D., Nagendra, L., Raizada, N., Bhattacharya, S., & Sharma, M. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_122_23 · Cited by 7
Takaike, H., Uchigata, Y., Nakagami, T., & Iwamoto, Y. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3294 · Cited by 7
Starting subcutaneous insulin doses in a paediatric population with newly diagnosed type 1 diabetes
Lemieux, L., Crawford, S. G., & Pacaud, D. (2010) · Paediatrics & Child Health · doi:10.1093/pch/15.6.357 · Cited by 7
Association between low C-peptide and fragility fractures in postmenopausal women without diabetes
Ferro, Y., Russo, C., Russo, D., Gazzaruso, C., Coppola, A., Gallotti, P., Zambianchi, V., Fodaro, M., Romeo, S., Galliera, E., et al. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0672-4 · Cited by 7
Sullivan, C. A. W., Cacicedo, J. M., Rajendran, I., & Steenkamp, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207065 · Cited by 7
Efficacy of oral versus insulin therapy for newly diagnosed diabetes in low-income settings.
Vaughan, E. M., Moreno, J. P., Hyman, D. J., Chen, T., & Foreyt, J. P. (2017) · PubMed · Cited by 7
A Role for Total Pancreatectomy and Islet Autotransplant in the Treatment of Chronic Pancreatitis
Bellin, M. D. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.425 · Cited by 7
Prevention of Type 1 Diabetes Mellitus
Pozzilli, P., & Guglielmi, C. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_49 · Cited by 7
Hendriks, E., Marcovecchio, M. L., Evans, M. L., Barker, P., Burling, K., Overbergh, L., & Mathieu, C. (2025) · Diabetes Care · doi:10.2337/dc25-0214 · Cited by 8
Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy
Michels, A. W., Gottlieb, P. A., Nelson, B., & Dayan, C. M. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70091 · Cited by 7
The evolution of C-peptide's role in diabetes care
Briggs, L., Read, A., Darch, S. J., Williams, E. L., Loh, W. J., & Kenkre, J. S. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000947 · Cited by 6
Kinney, M., You, L., Sims, E. K., Wherrett, D. K., Schatz, D., Lord, S. M., Krischer, J. P., Russell, W. E., Gottlieb, P. A., Libman, I. M., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad003 · Cited by 6
Metadata
- Authors
- Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W.
- Affiliations
- University of Minnesota (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 832-836
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1988519907
- Cited by
- 695
- References
- 25
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 30 · 2023: 34 · 2022: 39 · 2021: 49 · 2020: 38 · 2019: 29 · 2018: 31 · 2017: 32 · 2016: 30 · 2015: 44 · 2014: 32 · 2013: 53 · 2012: 37
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01RR000400, M01-RR00400)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, residual beta-cell function, C-peptide, diabetic retinopathy, diabetic nephropathy, albuminuria, severe hypoglycemia, intensive insulin therapy, diabetes complications, Diabetes Control and Complications Trial
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Islets of Langerhans, Male, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
